Punjab Chemicals Q3 FY26 Revenue Up 15.3% to ₹246.6 Cr, PAT Soars 127.7%
Punjab Chemicals & Crop Protection Ltd reported Q3 FY26 revenue of ₹246.6 Cr, up 15.3% YoY. PAT surged 127.7% to ₹13.8 Cr. 9M FY26 revenue grew 17.6% to ₹821.2 Cr with PAT up 66.2% to ₹53.0 Cr. Three export MOUs signed, and a new herbicide launched domestically. Capex of ~₹60 Cr planned over six quarters.
The significant growth in financial metrics, coupled with strategic initiatives like new product commercialization, export-oriented partnerships, and substantial capital expenditure plans, are expected to have a material impact on the company's future performance.
The company reported strong year-on-year growth in revenue, EBITDA, and PAT for both the quarter and nine-month periods. Strategic partnerships, new product launches, and planned capex indicate positive future prospects.
Punjab Chemicals & Crop Protection Limited (PCCPL) has announced its financial results for the third quarter (Q3) and nine months (9M) ended December 31, 2025. The company reported a revenue of ₹246.6 crore for Q3 FY26, marking a year-on-year growth of 15.3%, driven by improved domestic and export sales and increased demand. Gross margins stood at 41.9% for the quarter, attributed to product mix and efficiency gains. EBITDA for Q3 FY26 surged by 53.5% YoY to ₹29.6 crore, with EBITDA margins at 12.0%. Profit After Tax (PAT) for the quarter saw a substantial growth of 127.7% YoY, reaching ₹13.8 crore, with PAT margins at 5.6%.
For the nine months ended December 31, 2025, PCCPL's revenue was ₹821.2 crore, a 17.6% increase YoY. EBITDA for 9M FY26 was ₹90.6 crore, up 23.0% YoY, and PAT was ₹53.0 crore, a significant 66.2% growth YoY.
The company highlighted strategic partnerships, signing three MOUs for export-oriented products expected to be commercialized in FY27. Domestically, a new herbicide product was successfully commercialized in Q1 FY26. PCCPL is also working on additional products for commercialization over the next 2-3 quarters and has expanded its R&D facility at Derabassi, with a new project initiated at Lalru. Commercial production trials for four new products are underway in Q4 FY26, and a block shutdown is planned at Derabassi in Q4 to debottleneck capacity for new products.
PCCPL has earmarked approximately ₹60 crore for capex over the next six quarters, focusing on new manufacturing blocks and capacity debottlenecking. The company is also actively scouting for a new site to support its growing operations and product range, with a significant emphasis on export growth. The company's R&D expenditure is planned to double over the next two years, with a focus on developing high-value intermediates and expanding its catalogue products.
What to do with a filing like this
Punjab Chemicals & Crop Protection Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Punjab Chemicals & Crop Protection Limited. Read the original for the full detail.